Motif BioSciences, Inc.
Motif BioSciences, Inc. is applying proprietary technology and expertise in medicinal chemistry, biology and genomics to discover and develop best-in-class small molecule drugs and novel genetic targets that can be partnered out to the pharmaceutical industry for further development.
Motif was founded on the scientific premise of studying the genetic causes of common, complex diseases in relatively small and specialized populations. This approach has been validated in important discoveries in diabetes and hypertension in partnership with Imperial College London.
Motif has built on this foundation by adding a very experienced team of drug discovery scientists – former senior executives at Merck, Schering Plough, Wyeth, GlaxoSmithKline, and Bayer - in medicinal and computational chemistry, biology, toxicology, pharmacology, and clinical development to capitalize on the growing trend of pharmaceutical companies to outsource drug discovery to small specialized players.
Management
Zaki Hosny - Chief Executive Officer and Deputy Chairman
Frank LaSaracina - Chief Financial Officer, VP Business Development
Matthew J. Wyvratt, Ph.D. - Senior Vice President, Drug Discovery
Jerauld S. Skotnicki, Ph.D. - Executive Director, Medicinal Chemistry
Mark L. Greenlee, Ph.D. - Executive Director, Medicinal Chemistry
Simon K. Kearsley, Ph.D. - Executive Director, Computational Chemistry
Kevin Arnold, Ph.D. - Executive Director, Genomics
Faisal H.S. Al-Refaei, MD, MSc - Regional Director, Middle East
Joelle van der Walt, Ph.D. - Project Coordinator, Molecular Genetics
Manish Pungliya - Consultant, Bioinformatics
Board of Directors
Richard C.E. Morgan - (Chairman) Chief Executive Officer, Amphion Innovations
Jon Gold - Senior Financial Analyst, Federated Investments
Gerard Moufflet - President and Chief Executive Officer, Acceleration International
Dr. Mary Lake Polan - Board of Directors, Wyeth Corporation, formally Professor and Chair emeritus, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Dr. John Stakes - Director of Specialty Care Development, Harvard Medical School and Massachusetts General Hospital
Bruce Williams - Biotechnology Industry Consultant, formally held senior marketing positions at Celgene Corp., and Ortho Biotech, a Johnson & Johnson company
